C-reactive protein for predicting all-cause mortality in patients with acute ischemic stroke: a meta-analysis

Bo Yu1,2, Ping Yang2, Xuebi Xu1 and Lufei Shao2

1Department of Neurology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China; 2Department of Neurology, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China

Correspondence: Bo Yu (yubojinan01@21cn.com)

Studies on the association of C-reactive protein (CRP) with all-cause mortality in acute ischemic stroke patients have yielded conflicting results. The objective of this meta-analysis was to evaluate the prognostic value of CRP elevation in predicting all-cause mortality amongst patients with acute ischemic stroke. We searched the original observational studies that evaluated the association of CRP elevation with all-cause mortality in patients with acute ischemic stroke using PubMed and Embase databases until 20 January 2018. Pooled multivariate-adjusted hazard ratio (HR) with 95% confidence intervals (CI) of all-cause mortality was obtained for the highest compared with the lowest CRP level or per unit increment CRP level. A total of 3604 patients with acute ischemic stroke from eight studies were identified. Acute ischemic stroke patients with the highest CRP level were independently associated with an increased risk of all-cause mortality (HR: 2.07; 95% CI: 1.60–2.68) compared with the lowest CRP category. The pooled HR of all-cause mortality was 2.40 (95% CI: 1.10–5.21) for per unit increase in log-transformed CRP. Elevated circulating CRP level is associated with the increased risk of all-cause mortality in acute ischemic stroke patients. This meta-analysis supports the routine use of CRP for the death risk stratification in such patients.

Introduction

Stroke remains the second most common cause of death and the leading cause of disability worldwide [1]. Ischemic stroke is the most common type of stroke, comprising 87% of all types of stroke [2]. Ischemic stroke causing permanent disability is associated with a remarkable economic and social burden [3]. A decreasing trend in total mortality of ischemic stroke has been observed in many regions [4–6]. The markedly increased number of ischemic stroke survivors may be partly attributed to improvements in in-hospital management [7]. Despite the decline in overall ischemic stroke hospitalizations in the United States, the age-specific acute ischemic stroke hospitalization rates increased for patients aged 25–64 years [8]. Therefore, early prediction of outcomes after acute ischemic stroke is clinically important for optimized care.

Inflammation plays an important role in the pathophysiology of atherosclerosis and ischemic stroke [9,10]. Several inflammatory cytokines have been identified as cardiovascular and functional outcome predictors after ischemic stroke [11]. C-reactive protein (CRP) is a frequently studied inflammatory biomarker that is implicated in all stages of ischemic stroke [12]. Elevated CRP level is independently associated with the excessive risk of ischemic stroke [13]. However, studies on the association of CRP elevation and all-cause mortality risk in patients with acute ischemic stroke have yielded inconsistent results [14,15].
Previous meta-analysis only evaluated the association between CRP elevation and poor functional outcome but did not focus on the all-cause mortality outcome in patients with ischemic stroke [16]. To date, the prognostic value of CRP elevation in patients with acute ischemic stroke who have a high risk of death is still poorly studied.

Currently, no previous meta-analysis has quantitatively examined the association between CRP and all-cause mortality in patients with acute ischemic stroke. We aimed to evaluate the association of CRP elevation with all-cause mortality risk in patients with acute ischemic stroke by conducting a meta-analysis on available observational studies.

**Materials and methods**

**Data source and literature search**

This meta-analysis followed the reporting checklist of the Meta-analysis of Observational Studies in Epidemiology [17]. Two authors independently searched PubMed and Embase databases from their inception to 28 February 2018. Search terms included ‘C-reactive protein’ or ‘CRP’ and ‘mortality’ or ‘death’ or ‘survival’ and ‘stroke’ or ‘cerebral infarction’ or ‘cerebrovascular accident’. In addition, reference lists of all relevant articles were also manually checked to identify additional studies. Language was restricted to English.

**Study selection**

Studies were eligible if the following conditions were met: (i) enrolled adult patients with acute ischemic stroke; (ii) determined baseline CRP levels after the symptom onset of ischemic stroke or on admission; (iii) provided data on all-cause mortality; (iv) at least 3 months of follow-up duration; and (v) reported multivariable adjusted risk estimate of all-cause mortality associated with the CRP elevation or continuous value of CRP level. Studies were excluded if: (i) included hemorrhagic stroke patients; (ii) unadjusted risk estimate reported; (iii) functional outcome as the outcome of prognosis; and (iv) duplicated publication, conference abstracts, or letters.

**Data extraction and quality assessment**

The following data were abstracted from each of the eligible studies: first author, publication year, country of origin, study type, sample size, gender, median or mean age of patients, CRP cut-off value, follow-up duration, number of deaths, fully adjusted risk estimate, and adjustment for covariates. The methodological quality of each article was assessed using the Newcastle–Ottawa Scale (NOS) [18] and study achieving 7 or over points was regarded high quality. Any discrepancy between two authors was settled by discussion.

**Data analysis**

All statistical analyses were carried out with STATA (version 12.0, Stata, College Station, TX, U.S.A.). Summary risk ratio (RR) with 95% confidence intervals (CI) was pooled for comparison between the highest compared with the lowest [reference] category of CRP level or log-transformed per unit increase in CRP level. Between-study heterogeneity was tested using the $I^2$ statistic and Cochran's $Q$ test. $I^2 > 50\%$ or $P < 0.10$ for Cochran's $Q$ test indicate high heterogeneity. When significant heterogeneity was present, we applied a random-effect model. Otherwise, a fixed-effect model was selected. We performed the subgroup analyses by the study design [prospective or retrospective], length of follow-up [first 3 months compared with $>3$ months], geographic area [Europe compared with others], sampling time of the blood [within 72 h compared with 72 h to 15 days], cut-off values of CRP [single compared with $\geq 3$ categories], measurement of CRP [high-sensitivity compared with routine], and NOS [$\geq 7$ compared with $<7$ points]. Sensitivity analyses were performed using the leave-one-out method. Publication bias was evaluated using the Begg’s test and Egger’s test, with $P > 0.1$ indicating no statistical significance.

**Results**

**Search results and study characteristics**

Of the 538 relevant records obtained from the initial electronic search, 8 studies [15,19–25] were finally included in the meta-analysis. Figure 1 lists the detailed process of the study selection. The baseline characteristics of the selected studies are summarized in Table 1. A total of 3604 acute ischemic stroke patients were identified. The sample size of the included studies ranged from 228 to 741. Five studies [19,20,23–25] were prospective and three [15,21,22] were retrospective in nature. Five studies [15,19,21–23] were carried out in Europe, two in China [24,25], and one in the United States [20]. Follow-up duration ranged from 3 months to 7.4 years. Blood samples were collected on admission...
Table 1 Baseline characteristics of studies included in meta-analysis

| Author/year       | Region       | Study design            | Patients (% men) | Age/Range Mean (S.D.) | CRP cut-off value (mg/l) | Sampling time                     | Death numbers | HR/OR (95% CI) | Follow-up | Adjustment for covariates | Overall NOS |
|-------------------|--------------|-------------------------|------------------|-----------------------|-------------------------|-----------------------------------|----------------|----------------|-----------|--------------------------|-------------|
| Muir et al. 1999  | Scotland     | Prospective study       | AIS 228 (54.4)   | 67.0 ± 13.1           | Log-transformed per unit increase | Within 72 hours of admission | 81             | 1.23        | (1.13–1.35) | Age, NIHSS, TC, histories of previous MI, stroke, and cigarette smoking | 7           |
| Elkind et al. 2006| U.S.A.       | Prospective study       | AIS 467 (45.4)   | 68.9 ± 12.7           | Quartile 3 vs. 1; ≥31.2 vs. <4.2 (Hs-CRP) | Hospitalization or clinic visit | 159            | 2.11        | (1.18–3.75) | Age, sex, race/ethnicity, CAD, DM, hypertension, hyperlipidemia, AF, current smoking, stroke severity and Lp-PLA2 | 7           |
| Shantikumar et al.| U.K.         | Retrospective study     | AIS 394 (50.8)   | 58–81                 | Quintile 4 vs. 1; >22.3 vs. <2.48 | Within 10 days of symptom onset | 231            | 2.0         | (1.3–3.1)  | Age, AF, previous stroke/TIA, stroke subtype | 6           |
| den Hertog et al. | The Netherlands | Retrospective study    | AIS 561 (60.0)   | 69.7 ± 13.5           | ≥7.0 vs. <7.0 and log-transformed per unit increase | Within 12 h of symptom onset | 110            | 1.7         | (1.0–2.9), 1.9 | Age, sex, NIHSS, cigarette smoking, DM, hypertension, statin use, and stroke subtype | 7           |
| Idicula et al. 2009 | Norway      | Prospective study       | AIS 498 (60.6)   | 69.3 ± 14.0           | Quartile 3 vs. 1; >10.0 vs. <3.0 | Within 24 h | 67             | 3.47       | (1.58–7.64) | Age, sex, NIHSS, pre-existing DM and intravenous thrombolysis in categories | 8           |
| Huang et al 2012  | China        | Prospective study       | AIS 741 (74.9)   | 60.9 ± 13.3           | >3.0 vs. ≤3.0 (Hs-CRP) | Within 15 days of symptom onset | 32             | 6.48        | (1.41–29.8) | Age, sex, NIHSS, hypertension, CAD, and fasting glucose at admission | 6           |
| Karlinski et al. 2014 | Poland      | Retrospective study    | AIS 341 (32.9)   | 55–74                 | >5.0 vs. ≤5.0 | Within 24 h after admission | 53             | 1.32        | (0.51–3.37) | Age, baseline NIHSS, DM, CHF, lack of prestroke disability, recent infection and prestroke statins use | 7           |
| Li et al. 2015    | China        | Prospective cohort study | AIS 374 (55.1)  | 69 (63–79)            | Log-transformed per unit increase (Hs-CRP) | Within 12 h of symptom onset | 64             | 15.37       | (3.25–41.08) | Age, sex, smoking, glucose, NIHSS, homocysteine, procalcitonin, infarct volume, and rt-PA-treated | 7           |

Abbreviations: AF, atrial fibrillation; AIS, acute ischemic stroke; CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; HR, hazard ratio; Hs-CRP, high-sensitivity CRP; Lp-PLA2, lipoprotein-associated phospholipase A2; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale score; OR, odds ratio; rt-PA, recombinant tissue plasminogen activator.
or within 15 days of symptom onset. Two studies [20,24] measured CRP by means of a high-sensitivity method. The NOS score of the included studies ranged from 6 to 8 points, which could be considered as moderate to high quality.

**Categorical analysis of CRP with all-cause mortality**

Six studies [15,20–24] reported the all-cause mortality risk by the categorical analysis of CRP elevation. As shown in Figure 2, no significant heterogeneity across studies was found \( I^2 = 4.3\% \); \( P=0.389 \). Meta-analysis showed that the pooled hazard ratio (HR) of all-cause mortality for the highest compared with the lowest CRP category was 2.07 (95% CI: 1.60–2.68) in a fixed-effect model.

**Continuous analysis of CRP with all-cause mortality**

Three studies [19,22,25] reported the all-cause mortality risk by the continuous analysis of CRP increment. Meta-analysis showed that the pooled HR of all-cause mortality for per unit increase in log-transformed CRP was 2.40 (95% CI: 1.10–5.21) in a random-effect model (Figure 3). A leave-one-out sensitivity analysis demonstrated that removal individual study did not alter the overall pooled risk estimate in both categorical and continuous analyses (data not shown).
Figure 2. Forest plots showing RRs with 95% CIs of all-cause mortality for the highest compared with the lowest CRP level category

Figure 3. Forest plots showing RRs with 95% CIs of all-cause mortality for per unit increase in log-transformed CRP level

Subgroup analyses and publication bias
Subgroup analyses showed that the pooled HR of all-cause mortality was 1.80 (95% CI: 1.16–2.81) and 2.26 (95% CI: 1.65–3.08) in the first 3 months and more than 3 months follow-up, respectively. In addition, statistical associations were consistently observed in each subgroup (Table 2). No evidence of significant publication bias was found according to the Begg’s test ($P = 0.452$) and the Egger’s test ($P = 0.293$).

Discussion
This meta-analysis demonstrated that CRP elevation was independently associated with an increased risk of all-cause mortality in patients with acute ischemic stroke. Acute ischemic stroke patients with the highest CRP elevation had a 2.07-fold risk of all-cause mortality. Moreover, prognostic strength of CRP elevation was clearly supported by each
Table 2 Subgroup analyses of CRP elevation with acute ischemic stroke risk

| Subgroup                      | Number of studies | Pooled HR  | 95% CIs           | Heterogeneity between studies |
|-------------------------------|-------------------|------------|-------------------|-------------------------------|
| **Study design**              |                   |            |                   |                               |
| Prospective                   | 3                 | 2.72       | 1.74–4.25         | P = 0.308; I² = 15.0%         |
| Retrospective                 | 3                 | 1.80       | 1.31–2.47         | P = 0.710; I² = 0.0%          |
| **Region**                    |                   |            |                   |                               |
| Europe                        | 4                 | 1.97       | 1.47–2.66         | P = 0.396; I² = 0.0%          |
| Others                        | 2                 | 2.43       | 1.41–4.17         | P = 0.178; I² = 45.0%         |
| **Cut-off value of CRP**      |                   |            |                   |                               |
| Single                        | 3                 | 1.80       | 1.16–2.81         | P = 0.205; I² = 36.9%         |
| Tertile/Quartile              | 3                 | 2.22       | 1.62–3.06         | P = 0.476; I² = 0.0%          |
| **Sampling time**             |                   |            |                   |                               |
| Within 72 h                   | 4                 | 2.00       | 1.44–2.78         | P = 0.390; I² = 0.4%          |
| 10–15 days                    | 2                 | 2.18       | 1.44–3.32         | P = 0.146; I² = 52.6%         |
| **Measurement of CRP**        |                   |            |                   |                               |
| High-sensitivity              | 2                 | 2.43       | 1.41–4.17         | P = 0.178; I² = 45.0%         |
| Routine                       | 4                 | 1.97       | 1.47–2.65         | P = 0.396; I² = 0.0%          |
| **Follow-up duration**        |                   |            |                   |                               |
| First 3 months                | 3                 | 1.80       | 1.16–2.81         | P = 0.205; I² = 36.9%         |
| >3 months                     | 3                 | 2.22       | 1.62–3.06         | P = 0.476; I² = 0%            |
| **Study quality**             |                   |            |                   |                               |
| NOS ≥ 7                       | 4                 | 2.11       | 1.43–3.10         | P = 0.158; I² = 42.2%         |
| NOS < 7                       | 2                 | 2.04       | 1.44–2.89         | P = 0.885; I² = 0.0%          |

unit increase in log-transformed CRP by 2.40-fold all-cause mortality risk. These findings raise the possibility adding CRP to the prognostic model will improve the prediction of post-stroke death events.

Accurately predicting stroke prognosis is challenging. Blood biomarkers may provide useful information to improve the prediction of outcome after ischemic stroke [26]. Stroke prognosis can be classified by survival, neurological, and functional outcomes. The prognostic value of CRP in patients with acute ischemic stroke has been widely investigated. Elevated baseline higher CRP level could predict an unfavorable long-term functional outcome in patients with ischemic stroke [16]. However, the role of CRP in predicting the survival outcome amongst ischemic stroke remains controversial.

Subgroup analysis showed a stronger all-cause mortality risk in the studies with more than 3 months of follow-up than in the first 3 months. This finding may be partly explained by the highest risk of recurrent stroke and sudden cardiac death during the early period post stroke. CRP elevation can increase the risk of recurrent stroke [27,28], which was associated with an increased risk of death [29]. Sudden cardiac death may be the leading cause of post-stroke mortality because of the stronger association between CRP and cardiac injury [30,31]. Furthermore, exclusion of patients with an early infection during hospitalization did not significantly affect the association of CRP with mortality [22]. Thus, the predictive value of CRP in acute stroke appeared to be altered by early infection. Therefore, screening CRP level can improve the prediction of both long-term and short-time death events.

An important issue that has not been explored in the reports is the timing of blood sampling. Blood samples were collected from within 12 h to 15 days after the symptom onset or admission in the analyzed studies. However, our stratified analysis indicated that the pooled HR was similar in within 72 h and beyond 72 h time points of blood sampling subgroups. In-line with our results, CRP elevation within 30 days of stroke also highly predicted long-term survival [27]. Nevertheless, follow-up CRP elevation was an independent predictor of mortality after 90 days in patients with thrombolytic acute stroke [32]. Thus, using CRP level in predicting mortality regardless of the timing of blood sampling may be valid.

CRP elevation may reflect a systemic inflammatory response following ischemic stroke, the degree of stroke severity, or concurrent infections at the time of sampling. Stroke severity judged by the National Institutes of Health Stroke Scale score is strongly associated with mortality after ischemic stroke [33]. However, an elevated CRP level predicted future mortality independent of stroke severity. CRP elevation may also reflect a pre-existing atherosclerotic plaque or the presence of vascular risk factors. In addition, association of CRP with post-stroke mortality may partly reflect inflammation-induced endothelial cell dysfunction and platelet activation [21]. All these factors contributed to the excessive risk of post-stroke mortality.
This meta-analysis has several limitations. First, single CRP determination at baseline rather than several measures may have led to the misclassification of patients in each category. Second, an elevated CRP level may reflect a state of concurrent autoimmune diseases or chronic inflammatory disease during the study enrolment. Lack of adjustment for these conditions may have overestimated the prognostic significance of CRP. Third, various cut-off values of CRP elevation have been reported in the selected studies, and we could not determine an optimal threshold of the CRP. Fourth, all the patients were diagnosed with acute ischemic stroke, so the current findings could not be generalized to transient ischemic attack and hemorrhagic stroke. Furthermore, the prognostic role of CRP may also be affected by different phases or subtypes of ischemic stroke. Finally, elevated CRP level after thrombolysis treatment did not independently predict the outcome in patients with ischemic stroke, suggesting that tissue plasminogen activator may influence the prognostic significance of CRP [15]. Future studies of blood samples performed directly before the tissue plasminogen activator treatment are required.

In conclusion, patients with acute ischemic stroke that have elevated CRP levels have a significantly increased risk of all-cause mortality. CRP level measurement should be considered for post-stroke death risk stratification in patients with acute ischemic stroke. Future well-designed prospective studies should be conducted to assess the prognostic values of other inflammatory biomarkers or concurrently multiple markers in ischemic stroke patients.

**Author contribution**
P.Y. and X.X. made the literature search, extracted data, and evaluated the study quality. L.S. performed the statistical analysis. P.Y. drafted the manuscript. B.Y. designed the study, interpreted the results, and revised and approved the final manuscript.

**Competing interests**
The authors declare that there are no competing interests associated with the manuscript.

**Funding**
The authors declare that there are no sources of funding to be acknowledged.

**Abbreviations**
CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; NOS, Newcastle–Ottawa Scale.

**References**
1 Murray, C.J. and Lopez, A.D. (2013) Measuring the global burden of disease. *N. Engl. J. Med.* 369, 448–457, https://doi.org/10.1056/NEJMra1201534
2 Shiber, J.R., Fontane, E. and Adewale, A. (2010) Stroke registry: hemorrhagic vs ischemic strokes. *Am. J. Emerg. Med.* 28, 331–333, https://doi.org/10.1016/j.ajem.2008.10.026
3 Feigin, V.L., Norrving, B. and Mensah, G.A. (2017) Global burden of stroke. *Circ. Res.* 120, 439–448, https://doi.org/10.1161/CIRCRESAHA.116.308413
4 Hsieh, C.Y., Wu, D.P. and Sung, S.F. (2017) Trends in vascular risk factors, stroke performance measures, and outcomes in patients with first-ever ischemic stroke in Taiwan between 2000 and 2012. *J. Neurol. Sci.* 378, 80–84, https://doi.org/10.1016/j.jns.2017.05.002
5 Giang, K.W., Bjorck, L., Nielsen, S., Novak, M., Sandstrom, T.Z., Jern, C. et al. (2013) Twenty-year trends in long-term mortality risk in 17,149 survivors of ischemic stroke less than 55 years of age. *Stroke* 44, 3338–3343, https://doi.org/10.1161/STROKEAHA.113.002936
6 Krishnamurthi, R.V., Feigin, V.L., Forouzanfar, M.H., Mensah, G.A., Connor, M., Bennett, D.A. et al. (2013) Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet* 1, e259–e281, https://doi.org/10.1016/S2214-109X(13)70089-5
7 Minnerup, J., Wersching, H., Unrath, M. and Berger, K. (2015) Explaining the decrease of in-hospital mortality from ischemic stroke. *PLoS ONE* 10, e0131473, https://doi.org/10.1371/journal.pone.0131473
8 Ramirez, L., Kim-Tenser, M.A., Sanossian, N., Chen, S., Wen, G., He, S. et al. (2016) Trends in acute ischemic stroke hospitalizations in the United States. *J. Am. Heart Assoc.* 5, pii:003233, https://doi.org/10.1161/JAHA.116.003233
9 Libby, P. (2002) Inflammation in atherosclerosis. *Nature* 420, 868–874, https://doi.org/10.1038/nature01323
10 Chamorro, A. (2004) Role of inflammation in stroke and atherothrombosis. *Cerebrovasc. Dis.* 17, 1–5
11 Whiteley, W., Chong, W.L., Sengupta, A. and Sandercopp, P. (2009) Blood markers for the prognosis of ischemic stroke: a systematic review. *Stroke* 40, e380–e389, https://doi.org/10.1161/STROKEAHA.108.528752
12 Chamorro, A. and Hallenbeck, J. (2006) The harms and benefits of inflammatory and immune responses in vascular disease. *Stroke* 37, 291–293, https://doi.org/10.1161/01.STR.000020561.69611.88
13 Zhou, Y., Han, W., Gong, D., Man, C. and Fan, Y. (2016) Hs-CRP in stroke: a meta-analysis. *Clin. Chim. Acta* 453, 21–27, https://doi.org/10.1016/j.cca.2015.11.027
14 Dieplinger, B., Bocksrucker, C., Egger, M., Eggers, C., Haltmayer, M. and Mueller, T. (2017) Prognostic value of inflammatory and cardiovascular biomarkers for prediction of 90-day all-cause mortality after acute ischemic stroke-results from the Linz Stroke Unit Study. *Clin. Chem.* 63, 1101–1109, https://doi.org/10.1373/clinchem.2016.269969
15. Karlinski, M., Bembek, J., Grabska, K., Kobayashi, A., Baranowska, A., Litwin, T. et al. (2014) Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis. *Acta Neurol. Scand.* **130**, 305–311, https://doi.org/10.1111/ane.12227

16. VanGilder, R.L., Davido, D.M., Stinehart, K.R., Huber, J.D., Turner, R.C., Wilson, K.S. et al. (2014) C-reactive protein and long-term ischemic stroke prognosis. *J. Clin. Neurosci.* **21**, 547–553, https://doi.org/10.1016/j.jocn.2013.06.015

17. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D. et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group*. *JAMA* **283**, 2008–2012, https://doi.org/10.1001/jama.283.15.2008

18. Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M. et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed: 6 March 2018

19. Muir, K.W., Weir, C.J., Alwan, W., Squire, I.B. and Lees, K.R. (1999) C-reactive protein and outcome after ischemic stroke. *Stroke* **30**, 981–985, https://doi.org/10.1161/01.STR.30.5.981

20. Elkind, M.S., Tai, W., Coates, K., Paik, M.C. and Sacco, R.L. (2006) High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. *Arch. Intern. Med.* **166**, 2073–2080, https://doi.org/10.1001/archinte.166.19.2073

21. Shantikumar, S., Grant, P.J., Catto, A.J., Bambod, J.M. and Carter, A.M. (2009) Elevated C-reactive protein and long-term mortality after ischaemic stroke: relationship with markers of endothelial cell and platelet activation. *Stroke* **40**, 977–979, https://doi.org/10.1161/STROKEAHA.108.525105

22. den Hertog, H.M., van Rossum, J.A., van der Worp, H.B., van Gemert, H.M., de Jonge, R., Koudstaal, P.J. et al. (2009) C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. *J. Neurol. Sci.* **265**, 2003–2008, https://doi.org/10.1010/s00415-009-5228-x

23. Idicula, T.T., Brogger, J., Naess, H., Waje-Andreassen, U. and Thomassen, L. (2009) Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the ‘Bergen stroke study’. *BMC Neurol.* **9**, 18, https://doi.org/10.1186/1471-2377-9-18

24. Huang, Y., Jing, J., Zhao, X.Q., Wang, C.X., Wang, Y.L., Liu, G.F. et al. (2012) High-sensitivity C-reactive protein is a strong risk factor for death after acute ischemic stroke among Chinese. *CNS Neurosci. Ther.* **18**, 261–266, https://doi.org/10.1111/j.1755-5949.2012.00296.x

25. Li, Y.M. and Liu, X.Y. (2015) Serum levels of procalcitonin and high sensitivity C-reactive protein are associated with long-term mortality in acute ischemic stroke. *J. Neurol. Sci.* **352**, 68–73, https://doi.org/10.1016/j.jns.2015.03.032

26. Ng, G.J.L., Quek, A.M.L., Cheung, C., Arumugam, T.V. and Seet, R.C.S. (2017) Stroke biomarkers in clinical practice: a critical appraisal. *Neurochem. Int.* **107**, 11–22, https://doi.org/10.1016/j.neuint.2017.01.005

27. Whiteley, W., Jackson, C., Lewis, S., Lowe, G., Rumley, A., Sandercok, P. et al. (2011) Association of circulating inflammatory markers with recurrent vascular events after stroke: a prospective cohort study. *Stroke* **42**, 10–16, https://doi.org/10.1161/STROKEAHA.110.588954

28. Li, J., Zhao, X., Meng, X., Lin, J., Liu, L., Wang, C. et al. (2016) High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. *Stroke* **47**, 2025–2030, https://doi.org/10.1161/STROKEAHA.116.012901

29. Dhamoon, M.S., Sciacca, R.R., Rundek, T., Sacco, R.L. and Elkind, M.S. (2006) Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. *Neurology* **66**, 641–646, https://doi.org/10.1212/01.wnl.0000201253.93811.f6

30. Albert, C.M., Ma, J., Rifai, N., Stampfer, M.J. and Ridker, P.M. (2002) Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation* **105**, 2595–2599, https://doi.org/10.1161/01.CIR.0000017493.03108.1C

31. Zhu, L., Zou, Y., Wang, Y., Luo, X., Sun, K., Wang, H. et al. (2017) Prognostic significance of plasma high-sensitivity C-reactive protein in patients with hypertrophic cardiomyopathy. *J. Am. Heart Assoc.* **6**, pii:003233, https://doi.org/10.1161/JAHA.116.004529

32. Rocco, A., Ringleb, P.A., Grittner, U., Nolte, C.H., Schneider, A. and Nagel, S. (2015) Follow-up C-reactive protein level is more strongly associated with outcome in stroke patients than admission levels. *Neurosci. Res.* **86**, 2235–2241, https://doi.org/10.1016/j.neures.2015.11.005

33. Ghabaei, M., Zandieh, A., Mohebbi, S., Fakhri, M., Sadeghian, H., Divani, F. et al. (2014) Predictive ability of C-reactive protein for early mortality after ischemic stroke: comparison with NIHSS score. *Acta Neurol. Belg.* **114**, 41–45, https://doi.org/10.1007/s13760-013-0238-y